HeartWare bails on study evaluating LVAD in healthier patients

Tue, 10/16/2012 - 1:49pm
Mass Device

HeartWare backs out of a study assessing its left-ventricular assist devices in a lower-risk heart failure population, a move that analysts say won't affect the company's efforts to win FDA approval for treating higher-risk patients.

HeartWare logo

HeartWare International (NSDQ:HTWR) decided to back out of the REVIVE-IT study of its left-ventricular assist device, citing the need to focus efforts on the company's efforts to win FDA approval for the device.

The REVIVE-IT study, which the HeartWare had contributed about $600,000 to, was designed to evaluate the company's LVAD system in patients with lower-risk heart disease.

The decision to pull out of the study is "not too surprising," according to analysts at Leerink Swann.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.